Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 Regulatory T Cells (Tregs) in Human Cancers-Response.
作者信息
Sharma Anu, Subudhi Sumit K, Blando Jorge, Vence Luis, Wargo Jennifer, Allison James P, Ribas Antoni, Sharma Padmanee
机构信息
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
出版信息
Clin Cancer Res. 2019 Jun 1;25(11):3469-3470. doi: 10.1158/1078-0432.CCR-19-0402.
Abstract
摘要
相似文献
1
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 Regulatory T Cells (Tregs) in Human Cancers-Response.抗CTLA-4免疫疗法不会耗竭人类癌症中的FOXP3调节性T细胞（Tregs）——反应。
Clin Cancer Res. 2019 Jun 1;25(11):3469-3470. doi: 10.1158/1078-0432.CCR-19-0402.
2
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 Regulatory T Cells (Tregs) in Human Cancers-Letter.抗CTLA-4免疫疗法不会耗竭人类癌症中的FOXP3调节性T细胞（Tregs）——信函
Clin Cancer Res. 2019 Jun 1;25(11):3468. doi: 10.1158/1078-0432.CCR-18-3740. Epub 2018 Dec 4.
3
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 Regulatory T Cells (Tregs) in Human Cancers.抗 CTLA-4 免疫疗法不会耗尽人类癌症中的 FOXP3+调节性 T 细胞（Tregs）。
Clin Cancer Res. 2019 Feb 15;25(4):1233-1238. doi: 10.1158/1078-0432.CCR-18-0762. Epub 2018 Jul 27.
4
Identification of human regulatory T cells in the setting of T-cell activation and anti-CTLA-4 immunotherapy on the basis of expression of latency-associated peptide.基于潜伏相关肽的表达，在 T 细胞激活和抗 CTLA-4 免疫治疗的背景下鉴定人类调节性 T 细胞。
Cancer Discov. 2012 Feb;2(2):122-30. doi: 10.1158/2159-8290.CD-11-0236. Epub 2011 Dec 27.
5
[Influence of different cyto-stimuli on immunological activity of splenic regulatory T cells in mice].[不同细胞刺激对小鼠脾脏调节性T细胞免疫活性的影响]
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2007 Mar;19(3):142-5.
6
Tolerogenic dendritic cells suppress murine corneal allograft rejection by modulating CD28/CTLA-4 expression on regulatory T cells.调节性 T 细胞表面 CD28/CTLA-4 的表达抑制耐受树突状细胞抑制小鼠角膜同种异体移植排斥反应。
Cell Biol Int. 2014 Jul;38(7):835-48. doi: 10.1002/cbin.10268. Epub 2014 Mar 14.
7
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.通过 Fc 工程化抗 CTLA-4 抗体对肿瘤免疫中的人 Treg 和效应 T 细胞进行差异化控制。
Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):609-618. doi: 10.1073/pnas.1812186116. Epub 2018 Dec 26.
8
Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation.抑制FOXP3/NFAT相互作用可增强T细胞受体刺激后的T细胞功能。
J Immunol. 2015 Oct 1;195(7):3180-9. doi: 10.4049/jimmunol.1402997. Epub 2015 Aug 31.
9
IL-1R1 is expressed on both Helios(+) and Helios(-) FoxP3(+) CD4(+) T cells in the rheumatic joint.白细胞介素-1受体1（IL-1R1）在风湿性关节中的Helios(+)和Helios(-) FoxP3(+) CD4(+) T细胞上均有表达。
Clin Exp Immunol. 2015 Oct;182(1):90-100. doi: 10.1111/cei.12668. Epub 2015 Jul 30.
10
Increased expression of the regulatory T cell-associated marker CTLA-4 in bovine leukemia virus infection.牛白血病病毒感染中调节性T细胞相关标志物CTLA-4的表达增加。
Vet Immunol Immunopathol. 2015 Feb 15;163(3-4):115-24. doi: 10.1016/j.vetimm.2014.10.006. Epub 2014 Oct 25.
引用本文的文献
1
Fc Effector Function of Immune Checkpoint Blocking Antibodies in Oncology.肿瘤学中免疫检查点阻断抗体的Fc效应功能
Immunol Rev. 2024 Nov;328(1):334-349. doi: 10.1111/imr.13427. Epub 2024 Dec 11.
2
Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma.抗诱饵IL-18重塑肾细胞癌的肿瘤微环境并增强抗CTLA-4介导的排斥反应。
JCI Insight. 2024 Nov 19;10(1):e184545. doi: 10.1172/jci.insight.184545.
3
Tumor-immune hybrid cells evade the immune response and potentiate colorectal cancer metastasis through CTLA4.肿瘤免疫杂交细胞通过 CTLA4 逃避免疫反应并增强结直肠癌转移。
Clin Exp Med. 2024 Nov 5;25(1):2. doi: 10.1007/s10238-024-01515-9.
4
Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8 T cells.联合抗 PD-1 和抗 CTLA-4 治疗会产生包括祖细胞耗竭 CD8 T 细胞在内的克隆反应波。
Cancer Cell. 2024 Sep 9;42(9):1582-1597.e10. doi: 10.1016/j.ccell.2024.08.007. Epub 2024 Aug 29.
5
Deep phenotyping of nodal T-cell lymphomas reveals immune alterations and therapeutic targets.淋巴结T细胞淋巴瘤的深度表型分析揭示了免疫改变和治疗靶点。
Haematologica. 2025 Jan 1;110(1):129-141. doi: 10.3324/haematol.2023.284448.
6
Molecular patterns of resistance to immune checkpoint blockade in melanoma.黑色素瘤免疫检查点阻断治疗耐药的分子模式。
Nat Commun. 2024 Apr 9;15(1):3075. doi: 10.1038/s41467-024-47425-y.
7
Clinical and translational attributes of immune-related adverse events.免疫相关不良反应的临床和转化特征。
Nat Cancer. 2024 Apr;5(4):557-571. doi: 10.1038/s43018-024-00730-3. Epub 2024 Feb 15.
8
CTLA-4: Checkpoints beyond the membrane.CTLA-4：膜外的检查点。
Mol Ther. 2024 Feb 7;32(2):279-281. doi: 10.1016/j.ymthe.2024.01.002. Epub 2024 Jan 18.
9
XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer.XTX101，一种肿瘤激活、Fc 增强的抗 CTLA-4 单克隆抗体，在癌症小鼠模型中表现出肿瘤生长抑制和肿瘤选择性药效学。
J Immunother Cancer. 2023 Dec 12;11(12):e007785. doi: 10.1136/jitc-2023-007785.
10
A tumor-associated heparan sulfate-related glycosaminoglycan promotes the generation of functional regulatory T cells.一种与肿瘤相关的肝素硫酸相关糖胺聚糖促进功能性调节性 T 细胞的生成。
Cell Mol Immunol. 2023 Dec;20(12):1499-1512. doi: 10.1038/s41423-023-01096-9. Epub 2023 Nov 22.
本文引用的文献
1
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 Regulatory T Cells (Tregs) in Human Cancers.抗 CTLA-4 免疫疗法不会耗尽人类癌症中的 FOXP3+调节性 T 细胞（Tregs）。
Clin Cancer Res. 2019 Feb 15;25(4):1233-1238. doi: 10.1158/1078-0432.CCR-18-0762. Epub 2018 Jul 27.
2
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.Fc 效应功能有助于人类抗 CTLA-4 抗体的活性。
Cancer Cell. 2018 Apr 9;33(4):649-663.e4. doi: 10.1016/j.ccell.2018.02.010. Epub 2018 Mar 22.
3
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.黑色素瘤患者体内非经典单核细胞在体外对调节性T细胞的依匹木单抗依赖性细胞介导的细胞毒性作用
Proc Natl Acad Sci U S A. 2015 May 12;112(19):6140-5. doi: 10.1073/pnas.1417320112. Epub 2015 Apr 27.
4
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.IgG2a 同种型的抗 CTLA-4 抗体通过减少肿瘤内调节性 T 细胞增强抗肿瘤活性。
Cancer Immunol Res. 2013 Jul;1(1):32-42. doi: 10.1158/2326-6066.CIR-13-0013. Epub 2013 Apr 7.
5
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.Fc 依赖性耗竭肿瘤浸润调节性 T 细胞共同定义了抗 CTLA-4 治疗对黑色素瘤的疗效。
J Exp Med. 2013 Aug 26;210(9):1695-710. doi: 10.1084/jem.20130579. Epub 2013 Jul 29.
6
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.在单一部位耗尽肿瘤特异性 Tregs 可消除播散性肿瘤。
J Clin Invest. 2013 Jun;123(6):2447-63. doi: 10.1172/JCI64859.
7
CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.CTLA4 阻断诱导活化的淋巴细胞频繁浸润肿瘤，无论人类临床反应如何。
Clin Cancer Res. 2011 Jun 15;17(12):4101-9. doi: 10.1158/1078-0432.CCR-11-0407. Epub 2011 May 10.
Zotero 插件